Thursday, October 15, 2026

Regional Banks Hit With $135M Q4 Loan Prepayments as Depositors Reposition Ahead of Rate Shifts

Regional banks faced $135 million in loan prepayments during Q4 2025—nearly matching the first three quarters combined—as borrowers and depositors repositioned portfolios ahead of anticipated interest rate changes. The surge created funding mismatches despite stable annual loan growth, with total deposits declining $21 million in the quarter while $800 million in CDs mature through mid-2026.

Regional Banks Hit With $135M Q4 Loan Prepayments as Depositors Reposition Ahead of Rate Shifts
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Fourth-quarter loan payoffs at regional banks totaled $135 million in Q4 2025, nearly equaling the combined $140 million from the first three quarters, according to Andrew Hibshman. The prepayment spike represented 47% of all annual payoffs, creating unexpected liquidity management challenges.

Total deposits declined $21 million during the quarter, driven mainly by a $27.1 million drop in specific deposit categories, Hibshman reported. The outflows coincided with Treasury yield volatility—the 10-year benchmark swung from -0.6 to +10 basis points within one week, triggering portfolio repositioning across retail and commercial depositors.

Time deposits fell $38 million, an 18% annualized decline, as banks reduced exposure to high-cost funding, according to Darleen Gillespie. The drawdown comes as $800 million in CDs mature in the first two quarters of 2026, with weighted average rates creating repricing pressure, Michele Kawiecki noted.

The timing mismatch between accelerated loan prepayments and deposit volatility squeezed quarterly funding despite stable annual loan growth. Banks now face a concentration risk: roughly 40% of their CD book reprices within six months, potentially at lower rates if depositors seek alternative investments.

Peter Cahill emphasized the $135 million Q4 figure represented an anomaly compared to quarterly averages of $35-40 million earlier in 2025. The prepayment velocity suggests borrowers anticipated either refinancing opportunities or needed liquidity ahead of economic uncertainty.

Regional banks must now navigate $800 million in CD maturities while managing deposit pricing to retain customers. The Q4 dynamics indicate depositors are actively managing rate risk rather than maintaining static positions, forcing banks to compete on pricing or accept runoff.

Net interest margin compression is likely if banks increase CD rates to retain maturing deposits while loan yields decline from prepayments. The Q4 2025 pattern shows heightened sensitivity to rate expectations rather than actual Fed moves, complicating liquidity forecasting for 2026.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com